BMS Touts Breyanzi's Outpatient Administration As EU Approval Beckons

The US major won a positive opinion from the EU CHMP for Breyanzi with hopes the advantage of outpatient administration could help combat the lack of market impetus for CAR-T therapies.  

3D illustration of CAR-T cell attacking a cancer cell.
In CAR-T Therapy, The Patient's T-Cells Are Engineered Outside The Body. • Source: Alamy

Bristol Myers Squibb Company’s CAR-T therapy Breyanzi is set to enter the EU market for three lymphoma indications in advanced settings, with the firm touting outpatient administration as potentially boosting uptake in what has been a slow market.

Breyanzi (lisocabtagene maraleucel) received a positive opinion from the European Committee for Medicinal Products for Human Use (CHMP) for the...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anticancer

More from Therapeutic Category